ZA782648B
(en)
*
|
1977-05-23 |
1979-06-27 |
Ici Australia Ltd |
The prevention,control or eradication of infestations of ixodid ticks
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
JP2762522B2
(ja)
|
1989-03-06 |
1998-06-04 |
藤沢薬品工業株式会社 |
血管新生阻害剤
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
US5892112A
(en)
|
1990-11-21 |
1999-04-06 |
Glycomed Incorporated |
Process for preparing synthetic matrix metalloprotease inhibitors
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
AU658646B2
(en)
|
1991-05-10 |
1995-04-27 |
Rhone-Poulenc Rorer International (Holdings) Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
US5262564A
(en)
|
1992-10-30 |
1993-11-16 |
Octamer, Inc. |
Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
CA2148484A1
(en)
|
1992-11-13 |
1994-05-26 |
Stewart Lyman |
Novel cytokine designated elk ligand
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
US5612340A
(en)
|
1993-10-01 |
1997-03-18 |
Ciba-Geigy Corporation |
Pyrimidineamine derivatives and processes for the preparation thereof
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
CA2175215C
(en)
|
1993-11-19 |
2008-06-03 |
Yat Sun Or |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
BR9408323A
(pt)
|
1993-12-17 |
1997-08-19 |
Sandoz Ag |
Derivados de rapamicina
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
AU2096895A
(en)
|
1994-03-07 |
1995-09-25 |
Sugen, Incorporated |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
JPH09512167A
(ja)
|
1994-04-15 |
1997-12-09 |
アムジエン・インコーポレーテツド |
Hek5、hek7、hek8、hek11、新規なeph様受容体タンパク質チロシンキナーゼ
|
ES2109796T3
(es)
|
1994-05-03 |
1998-01-16 |
Ciba Geigy Ag |
Derivados de pirrolopirimidilo con efecto antiproliferante.
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
WO1996030347A1
(en)
|
1995-03-30 |
1996-10-03 |
Pfizer Inc. |
Quinazoline derivatives
|
DE69609602T2
(de)
|
1995-04-03 |
2001-04-12 |
Novartis Ag |
Pyrazolderivate und verfahren zu deren herstellung
|
DK0821671T3
(da)
|
1995-04-20 |
2001-04-23 |
Pfizer |
Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
KR100400620B1
(ko)
|
1995-06-09 |
2004-02-18 |
노파르티스 아게 |
라파마이신유도체
|
DK0836605T3
(da)
|
1995-07-06 |
2002-05-13 |
Novartis Ag |
Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
DK0780386T3
(da)
|
1995-12-20 |
2003-02-03 |
Hoffmann La Roche |
Matrixmetalloproteaseinhibitorer
|
JP4275733B2
(ja)
|
1996-01-23 |
2009-06-10 |
ノバルティス アクチエンゲゼルシャフト |
ピロロピリミジンおよびその製造法
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE59710417D1
(de)
|
1996-03-15 |
2003-08-14 |
Novartis Ag |
N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG
|
EP0892789B2
(en)
|
1996-04-12 |
2009-11-18 |
Warner-Lambert Company LLC |
Irreversible inhibitors of tyrosine kinases
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
DE69734513T2
(de)
|
1996-06-24 |
2006-07-27 |
Pfizer Inc. |
Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
|
AU735648B2
(en)
|
1996-07-12 |
2001-07-12 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
CN1230185A
(zh)
|
1996-07-13 |
1999-09-29 |
葛兰素集团有限公司 |
双环芳杂环化合物用作蛋白质酪氨酸激酶的抑制剂
|
EP0912559B1
(en)
|
1996-07-13 |
2002-11-06 |
Glaxo Group Limited |
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
ES2175415T3
(es)
|
1996-07-18 |
2002-11-16 |
Pfizer |
Inhibidores de metaloproteasas matriciales basados en fosfinato.
|
AU4055697A
(en)
|
1996-08-16 |
1998-03-06 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
CA2262421C
(en)
|
1996-08-23 |
2007-10-02 |
Novartis Ag |
Substituted pyrrolopyrimidines and processes for their preparation
|
EA199900139A1
(ru)
|
1996-08-23 |
1999-08-26 |
Пфайзер, Инк. |
Производные арилсульфониламиногидроксамовой кислоты
|
WO1998014449A1
(en)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Fused pyrazole derivatives and processes for their preparation
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
WO1998014450A1
(en)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Pyrimidine derivatives and processes for the preparation thereof
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
PT950059E
(pt)
|
1997-01-06 |
2004-10-29 |
Pfizer |
Derivados de sulfona ciclicos
|
EA002594B1
(ru)
|
1997-02-03 |
2002-06-27 |
Пфайзер Продактс Инк. |
Производные арилсульфониламиногидроксамовой кислоты
|
AU749750B2
(en)
|
1997-02-05 |
2002-07-04 |
Warner-Lambert Company |
Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
|
CA2279863A1
(en)
|
1997-02-07 |
1998-08-13 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
JP3710489B2
(ja)
|
1997-02-11 |
2005-10-26 |
ファイザー・インク |
アリールスルホニルヒドロキサム酸誘導体
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
WO1999007701A1
(en)
|
1997-08-05 |
1999-02-18 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
EP1003720B1
(en)
|
1997-08-08 |
2004-03-31 |
Pfizer Products Inc. |
Aryloxyarylsulfonylamino hydroxamic acid derivatives
|
EP1025228A4
(en)
|
1997-10-21 |
2002-09-18 |
Human Genome Sciences Inc |
HUMAN PROTEIN TR11, TR11SV1 AND TR11SV2 SIMILAR TO THE TUMOR NECROSIS FACTOR RECEPTOR
|
WO1999024440A1
(en)
*
|
1997-11-11 |
1999-05-20 |
Pfizer Products Inc. |
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
CA2319236A1
(en)
|
1998-02-09 |
1999-08-12 |
Genentech, Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
JP2002505330A
(ja)
|
1998-03-04 |
2002-02-19 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヘテロシクロ−置換イミダゾピラジン・たんぱくチロシンキナーゼ抑制剤
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
AU759226B2
(en)
|
1998-05-29 |
2003-04-10 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
WO2000002871A1
(en)
|
1998-07-10 |
2000-01-20 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
JP2002523459A
(ja)
|
1998-08-31 |
2002-07-30 |
メルク エンド カムパニー インコーポレーテッド |
新規血管形成阻害剤
|
ATE260255T1
(de)
|
1998-11-05 |
2004-03-15 |
Pfizer Prod Inc |
5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
|
EP1165085B1
(en)
|
1999-03-30 |
2006-06-14 |
Novartis AG |
Phthalazine derivatives for treating inflammatory diseases
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
AU783960B2
(en)
|
1999-06-07 |
2006-01-05 |
Immunex Corporation |
Tek antagonists
|
WO2001003720A2
(en)
|
1999-07-12 |
2001-01-18 |
Genentech, Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
|
EP1212331B1
(en)
|
1999-08-24 |
2004-04-21 |
Ariad Gene Therapeutics, Inc. |
28-epirapalogs
|
ES2306306T3
(es)
|
1999-11-05 |
2008-11-01 |
Astrazeneca Ab |
Nuevos derivados de quinazolina.
|
AU1928501A
(en)
|
1999-11-24 |
2001-06-04 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
DK1257632T3
(da)
|
2000-02-24 |
2008-01-28 |
Xcyte Therapies Inc |
Samtidig stimulering og opkoncentrering af celler
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
AU4721901A
(en)
|
2000-02-25 |
2001-09-03 |
Immunex Corp |
Integrin antagonists
|
JP2002105081A
(ja)
*
|
2000-07-28 |
2002-04-10 |
Nikken Chem Co Ltd |
新規チオフェンニ環化合物
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
WO2002026745A1
(fr)
*
|
2000-09-29 |
2002-04-04 |
Nippon Soda Co., Ltd. |
Composes de thienopyrimidine et leurs sels et procede de preparation
|
NZ526542A
(en)
|
2000-12-21 |
2005-01-28 |
Glaxo Group Ltd |
Pyrimidineamines as angiogenesis modulators
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
AU2002364211A1
(en)
*
|
2001-12-21 |
2003-07-15 |
Bayer Pharmaceuticals Corporation |
Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
JP4638876B2
(ja)
|
2003-05-23 |
2011-02-23 |
ワイス |
Gitrリガンド及びgitrリガンド関連分子及び抗体及びその使用
|
JP4755981B2
(ja)
|
2003-07-08 |
2011-08-24 |
ノバルティス アーゲー |
骨減少の処置のための、ラパマイシンおよびラパマイシン誘導体の使用
|
EP1648900A4
(en)
|
2003-07-11 |
2010-02-10 |
Ariad Pharma Inc |
PHOSPHORUS MACROCYCLES
|
EP1660126A1
(en)
|
2003-07-11 |
2006-05-31 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
TW200523262A
(en)
|
2003-07-29 |
2005-07-16 |
Smithkline Beecham Corp |
Inhibitors of AKT activity
|
GB0320300D0
(en)
*
|
2003-08-29 |
2003-10-01 |
Cancer Rec Tech Ltd |
Pyrimidothiophene compounds
|
JP2007518399A
(ja)
|
2003-12-02 |
2007-07-12 |
ジェンザイム コーポレイション |
肺癌を診断および治療する組成物並びに方法
|
US20080058431A1
(en)
|
2004-03-26 |
2008-03-06 |
Gen-Sheng Feng |
Modulators of Shp2 Tyrosine Phosphatase and Their Use in the Treatment of Body Weight Disorders
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
WO2006083289A2
(en)
|
2004-06-04 |
2006-08-10 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
WO2006021884A2
(en)
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
MX2007004489A
(es)
|
2004-10-13 |
2007-09-21 |
Wyeth Corp |
Analogos de 17-hidroxiwortamina como inhibidores pi3k.
|
CN101084224B
(zh)
*
|
2004-10-21 |
2013-12-04 |
美国陶氏益农公司 |
具有杀真菌活性的噻吩并-嘧啶化合物
|
PT1866339E
(pt)
|
2005-03-25 |
2013-09-03 |
Gitr Inc |
Moléculas de ligação a gitr e suas utilizações
|
CN101213297B
(zh)
|
2005-05-09 |
2013-02-13 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
BRPI0616202A2
(pt)
|
2005-09-20 |
2011-06-14 |
Pfizer Prod Inc |
formas de dosagem e uso de um inibidor da tirosina quinase
|
EP1981969A4
(en)
|
2006-01-19 |
2009-06-03 |
Genzyme Corp |
ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
|
WO2007117699A2
(en)
|
2006-04-07 |
2007-10-18 |
University Of South Florida |
Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-87877, nsc-117199 and their analogs
|
NZ578162A
(en)
|
2006-12-07 |
2011-12-22 |
Genentech Inc |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
WO2008124815A1
(en)
|
2007-04-10 |
2008-10-16 |
University Of South Florida |
Method of activating nk cells
|
JP5932217B2
(ja)
|
2007-07-12 |
2016-06-08 |
ジーアイティーアール, インコーポレイテッド |
Gitr結合分子を使用する併用療法
|
AU2008298948B2
(en)
|
2007-09-12 |
2014-09-04 |
F. Hoffmann-La Roche Ag |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
WO2009049098A2
(en)
|
2007-10-09 |
2009-04-16 |
Indiana University Research & Technology Corporation |
Materials and methods for regulating the activity of phosphatases
|
CN101909631B
(zh)
|
2007-10-25 |
2012-09-12 |
健泰科生物技术公司 |
制备噻吩并嘧啶化合物的方法
|
WO2009135000A2
(en)
|
2008-04-30 |
2009-11-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs
|
KR20110044992A
(ko)
|
2008-07-02 |
2011-05-03 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
TGF-β 길항제 다중-표적 결합 단백질
|
US9174969B2
(en)
|
2008-07-21 |
2015-11-03 |
University Of South Florida |
Indoline scaffold SHP-2 inhibitors and cancer treatment method
|
WO2010030002A1
(ja)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性gitrリガンド発現細胞
|
KR101703941B1
(ko)
*
|
2008-11-10 |
2017-02-07 |
내셔날 헬스 리서치 인스티튜트 |
티로신 키나아제 억제제로서의 접합 이환 및 삼환 피리미딘 화합물
|
WO2010121212A2
(en)
|
2009-04-17 |
2010-10-21 |
H. Lee Moffit Cancer Center And Research Institute, Inc. |
Indoline scaffold shp-2 inhibitors and method of treating cancer
|
US9567318B2
(en)
|
2009-08-17 |
2017-02-14 |
Memorial Sloan-Kettering Cancer Center |
Substituted pyrimidine compounds and uses thereof
|
WO2011028683A1
(en)
|
2009-09-03 |
2011-03-10 |
Schering Corporation |
Anti-gitr antibodies
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
ME02505B
(me)
|
2009-12-29 |
2017-02-20 |
Aptevo Res & Development Llc |
Heterodimerni vezujući proteini i njihove upotrebe
|
US8637684B2
(en)
|
2010-05-12 |
2014-01-28 |
Wisconsin Alumni Research Foundation |
Tautomycetin and tautomycetin analog biosynthesis
|
WO2012041524A1
(en)
|
2010-10-01 |
2012-04-05 |
Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) |
Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors
|
JP5961187B2
(ja)
*
|
2010-12-20 |
2016-08-02 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン
|
DK2937349T3
(en)
|
2011-03-23 |
2017-02-20 |
Amgen Inc |
CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
US20150352131A1
(en)
|
2013-01-16 |
2015-12-10 |
Rhode Island Hospital |
Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis
|
AP2015008656A0
(en)
|
2013-03-15 |
2015-08-31 |
Novartis Ag |
Antibody drug conjugates
|
AU2014256984B2
(en)
|
2013-04-26 |
2019-02-14 |
Indiana University Research & Technology Corporation |
Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)
|
WO2015000959A1
(en)
*
|
2013-07-03 |
2015-01-08 |
Norwegian University Of Science And Technology (Ntnu) |
4-amino-6-aryl[2,3-d]pyrimidines for the inhibition of egfr tyrosine kinase
|
AU2014284279A1
(en)
|
2013-07-03 |
2016-02-18 |
Beth Israel Deaconess Medical Center, Inc. |
SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors
|
EP2826586A1
(en)
|
2013-07-18 |
2015-01-21 |
Siemens Aktiengesellschaft |
A method and a system for machining an object
|
US9815813B2
(en)
|
2014-01-17 |
2017-11-14 |
Novartis Ag |
1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
|
CN105899491B
(zh)
|
2014-01-17 |
2019-04-02 |
诺华股份有限公司 |
用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物
|
CN105418632B
(zh)
*
|
2014-09-19 |
2020-02-21 |
上海创诺医药集团有限公司 |
噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
|
WO2016077793A1
(en)
|
2014-11-14 |
2016-05-19 |
Children's Hospital Medical Center |
Sos1 inhibitors for cancer treatment
|
EP4115882A1
(en)
*
|
2015-01-16 |
2023-01-11 |
The General Hospital Corporation |
Compounds for improving mrna splicing
|
US20180121597A1
(en)
|
2015-05-22 |
2018-05-03 |
Allosta Pharmaceuticals |
Methods to Prepare and Employ Binding Site Models for Modulation of Phosphatase Activity and Selectivity Determination
|
WO2016196591A1
(en)
|
2015-06-01 |
2016-12-08 |
Indiana University Research & Technology Corporation |
Protein tyrosine phosphatases or shp2 inhibitors and uses thereof
|
WO2016203406A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
WO2016203404A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
JP6878316B2
(ja)
|
2015-06-19 |
2021-05-26 |
ノバルティス アーゲー |
Shp2の活性を阻害するための化合物および組成物
|
WO2017078499A2
(ko)
|
2015-11-06 |
2017-05-11 |
경북대학교 산학협력단 |
단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
|
US11008372B2
(en)
|
2015-11-07 |
2021-05-18 |
Board Of Regents, The University Of Texas System |
Targeting proteins for degradation
|
US9932288B2
(en)
|
2015-12-09 |
2018-04-03 |
West Virginia University |
Chemical compound for inhibition of SHP2 function and for use as an anti-cancer agent
|
WO2017156397A1
(en)
|
2016-03-11 |
2017-09-14 |
Board Of Regents, The University Of Texas Sysytem |
Heterocyclic inhibitors of ptpn11
|
CN109071567B
(zh)
*
|
2016-05-19 |
2021-03-23 |
四川大学 |
抗流感小分子化合物及其制备方法和用途
|
JP7044375B2
(ja)
|
2016-05-31 |
2022-03-30 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
Ptpn11の複素環式阻害剤
|
EA201990001A1
(ru)
|
2016-06-07 |
2019-05-31 |
Джакобио Фармасьютикалс Ко., Лтд. |
Новые гетероциклические производные, применимые в качестве ингибиторов shp2
|
IL264186B1
(en)
|
2016-07-12 |
2024-04-01 |
Revolution Medicines Inc |
2,5-dimutomers of 3-methylpyrazines and 2,5,6-dimutomers of 3-methylpyrazines as allosteric SHP2 inhibitors
|
WO2018115380A1
(en)
*
|
2016-12-22 |
2018-06-28 |
Boehringer Ingelheim International Gmbh |
Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
|
WO2018129402A1
(en)
|
2017-01-06 |
2018-07-12 |
Oregon Health & Science University |
Compositions and methods used in diagnosing and treating colorectal cancer
|
US20190343836A1
(en)
|
2017-01-10 |
2019-11-14 |
Novartis Ag |
Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
|
GB201700814D0
(en)
*
|
2017-01-17 |
2017-03-01 |
Liverpool School Tropical Medicine |
Compounds
|
CN110431134A
(zh)
|
2017-01-23 |
2019-11-08 |
锐新医药公司 |
作为变构shp2抑制剂的吡啶化合物
|
IL296456A
(en)
|
2017-01-23 |
2022-11-01 |
Revolution Medicines Inc |
Bicyclics as allosteric shp2 inhibitors
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
WO2018172250A1
(en)
*
|
2017-03-21 |
2018-09-27 |
Bayer Pharma Aktiengesellschaft |
2-methyl-quinazolines
|
US10988466B2
(en)
|
2017-03-23 |
2021-04-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Heterocyclic derivatives useful as SHP2 inhibitors
|
RU2019138161A
(ru)
|
2017-05-02 |
2021-06-02 |
Революшн Медсинз, Инк. |
АНАЛОГИ РАПАМИЦИНА КАК ИНГИБИТОРЫ mTOR
|
BR112020004246A2
(pt)
|
2017-09-07 |
2020-09-01 |
Revolution Medicines, Inc. |
composições inibidoras de shp2 e métodos para o tratamento de câncer
|
CN111201223B
(zh)
|
2017-09-11 |
2024-07-09 |
克鲁松制药公司 |
SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
|
IL312291A
(en)
|
2018-05-01 |
2024-06-01 |
Revolution Medicines Inc |
C-26-linked rapamycin analogs as MTOR inhibitors
|
FI3788049T3
(fi)
|
2018-05-01 |
2023-05-30 |
Revolution Medicines Inc |
C40-, c28- ja c-32-liittyneitä rapamysiinianalogeja mtor-estäjinä
|